Abstract
In their review, Arslan et al[1] did not describe the status of Helicobacter pylori (H. pylori) treatment with furazolidone and the resistance to this antibiotic. We have presented different surveys showing the resistance of H. pylori to furazolidone from Asia and South America. The resistance rates varied but were mostly low (< 5%). There are not enough data on its efficacy and resistance in the United States and Europe. H. pylori mutations occurring in the oorD gene, including A041G, A122G, C349A(G), A78G, A112G, A335G, C156T and C165T, and in the porD gene, including G353A, A356G, C357T, C347T, C347G and C346A, have been indicated to be possibly related to the observed resistance. Additionally, to complete Arslan et al’s statement regarding levofloxacin resistance, it should be noted that compound mutations of N87A, A88N and V65I at codon Asn-87 were recently observed in the gyrA gene for the first time. However, the results on these topics are not sufficient, and more worldwide studies are suggested.
Keywords: Susceptibility, Furazolidone, Helicobacter pylori, Resistance, Levofloxacin, Treatment
Core tip: We have presented different surveys showing the resistance of Helicobacter pylori (H. pylori) to furazolidone from Asia and South America. The resistance rates varied but were mostly low (< 5%). H. pylori mutations occurring in the oorD gene, including A041G, A122G, C349A(G), A78G, A112G, A335G, C156T and C165T, and in the porD gene, including G353A, A356G, C357T, C347T, C347G and C346A, have been indicated to be possibly related to the observed resistance. Regarding levofloxacin resistance, compound mutations of N87A, A88N and V65I at codon Asn-87 were recently observed in the gyrA gene for the first time.
TO THE EDITOR
We have read with great interest the valuable article by Arslan et al[1], titled “Importance of antimicrobial susceptibility testing for the management of eradication in Helicobacter pylori infection”. One of the main subjects of the review was the description of the resistance rates of different antibiotics and the potential mechanisms leading to decreased in Helicobacter pylori (H. pylori) antimicrobial susceptibility. However, the authors should consider clarifying two important issues.
The authors did not allude to the status of H. pylori treatment with furazolidone and the resistance to this antibiotic. We have provided existing surveys reporting the resistance of H. pylori to furazolidone in Table 1. The resistance rates have been mostly reported to be lower than 5%; however, these rates can vary geographically. Furazolidone is not used widely in the United States and Europe; therefore, there are not enough data on its efficacy and resistance in these regions.
Table 1.
Studies evaluating the Helicobacter pylori resistance to furazolidone
Continent | Country | Study year | Strains (n) | Method | Resistance (%) | Author |
Asia | China (Shanghai) | 2000-2009 | 293 | Agar dilution | 0 | Sun et al[6] |
China (Zhejiang) | 2010-2012 | 21 | Agar dilution | 0.1 | Su et al[7] | |
China (Zhejiang) | 2009-2014 | 9687 | Agar dilution | < 0.01 | Ji et al[8] | |
India (Ghaziabad and New Delhi) | NA | 68 | Agar dilution | 22.1 | Gehlot et al[9] | |
India (Gujarat) | 2008-2011 | 80 | Disk diffusion | 13.8 | Pandya et al[10] | |
Iran (Rasht) | 2012-2014 | 169 | Disk diffusion | 61.9 | Maleknejad et al[11] | |
Iran (Shiraz) | 2004-2005 | 106 | Agar dilution | 9.4 | Kohanteb et al[12] | |
Iran (Sari) | 2009 | 197 | Disk diffusion | 61.4 | Abadi et al[13] | |
Iran (Tehran) | 2001-2004 | 135 | Disk diffusion | 0 | Siavoshi et al[14] | |
Iran (Tehran) | 2002-2003 | 24 | Disk diffusion | 0 | Fallahi et al[15] | |
Iran (Tehran) | 2005-2008 | 110 | Disk diffusion | 4.5 | Siavoshi et al[16] | |
Iran (Tehran) | 2007-2008 | 104 | Disk diffusion | 0 | Sirous et al[17] | |
Iran | 2003-2005 | 100 | Disk diffusion | 9 | Rafeey et al[18] | |
South Korea | 1994-1999 | 220 | Agar dilution | 1.4 | Kim et al[19] | |
Malaysia (Malacca) | 2009 | 90 | Epsilometer test | 0 | Goh et al[20] | |
Pakistan (Karachi) | 2008-2013 | 93 | disk diffusion | 4.3 | Siddiqui et al[21] | |
South America | Brazil (Bragança Paulista) | NA | 90 | Agar dilution | 4 | Mendonça et al[22] |
Brazil (Bragança Paulista) | NA | 138 | Agar dilution | 13 | Godoy et al[23] | |
Brazil (Sao Paulo) | NA | 39 | Agar dilution | 0 | Eisig et al[24] | |
Brazil (Sao Paulo) | 2008-2009 | 77 | Agar dilution and disk diffusion | 0 | Ogata et al[25] | |
Brazil (Sao Paulo) | 2008-2009 | 77 | Agar dilution | 0 | Ogata et al[26] |
One of the main reasons for the emergence of resistance is related to the extensive use of furazolidone. In addition, regarding the molecular mechanisms, some genetic mutations have been identified. Mutations occurring in the 2-oxoglutarate:acceptor oxidoreductase (oorD) gene, including A041G, A122G, C349A(G), A78G, A112G, A335G, C156T and C165T, and in the pyruvate oxidoreductase (porD) gene, including G353A, A356G, C357T, C347T, C347G and C346A, are possibly related to the resistance[2,3]. The oor and por genes are involved in the generation of acetyl coenzyme A (acetyl-CoA) and succinyl-CoA[4]. Despite these findings, additional molecular methods are proposed to reach a better understanding of the mechanisms that were mentioned.
Arslan et al[1] accurately documented the mechanism of levofloxacin resistance; i.e., point mutations in the gyrA (DNA gyrase) gene were stated to be potentially linked to the resistance. However, to complete their statement, it should be noted that compound mutations of N87A, A88N and V65I at codon Asn-87 were recently observed in the gyrA gene for the first time. L45F, A55S, A97V, D91N, R130K and G60S are other possible mutations that need to be assessed in studies with broader sample bases[5].
Footnotes
Manuscript source: Unsolicited manuscript
Specialty type: Gastroenterology and hepatology
Country of origin: Iran
Peer-review report classification
Grade A (Excellent): 0
Grade B (Very good): 0
Grade C (Good): C, C, C
Grade D (Fair): 0
Grade E (Poor): 0
Conflict-of-interest statement: The authors declared no conflict of interest.
Peer-review started: June 30, 2017
First decision: July 13, 2017
Article in press: August 15, 2017
P- Reviewer: Ananthakrishnan N, Bao ZJ, Jamali R S- Editor: Ma YJ L- Editor: A E- Editor: Huang Y
Contributor Information
Mohammad Zamani, Student Research Committee, Babol University of Medical Sciences, Babol 47176-47745, Iran; Cancer Research Center, Health Research Institute, Babol University of Medical Sciences, Babol 47176-47745, Iran.
Arash Rahbar, Student Research Committee, Babol University of Medical Sciences, Babol 47176-47745, Iran.
Javad Shokri-Shirvani, Department of Internal Medicine, Babol University of Medical Sciences, Babol 47176-47745, Iran. j.shokri@mubabol.ac.ir.
References
- 1.Arslan N, Yılmaz Ö, Demiray-Gürbüz E. Importance of antimicrobial susceptibility testing for the management of eradication in Helicobacter pylori infection. World J Gastroenterol. 2017;23:2854–2869. doi: 10.3748/wjg.v23.i16.2854. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 2.Su Z, Xu H, Zhang C, Shao S, Li L, Wang H, Wang H, Qiu G. Mutations in Helicobacter pylori porD and oorD genes may contribute to furazolidone resistance. Croat Med J. 2006;47:410–415. [PMC free article] [PubMed] [Google Scholar]
- 3.Dong F, Ji D, Huang R, Zhang F, Huang Y, Xiang P, Kong M, Nan L, Zeng X, Wu Y, et al. Multiple Genetic Analysis System-Based Antibiotic Susceptibility Testing in Helicobacter pylori and High Eradication Rate With Phenotypic Resistance-Guided Quadruple Therapy. Medicine (Baltimore) 2015;94:e2056. doi: 10.1097/MD.0000000000002056. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 4.Hughes NJ, Clayton CL, Chalk PA, Kelly DJ. Helicobacter pylori porCDAB and oorDABC genes encode distinct pyruvate:flavodoxin and 2-oxoglutarate:acceptor oxidoreductases which mediate electron transport to NADP. J Bacteriol. 1998;180:1119–1128. doi: 10.1128/jb.180.5.1119-1128.1998. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 5.Phan TN, Santona A, Tran VH, Tran TN, Le VA, Cappuccinelli P, Rubino S, Paglietti B. High rate of levofloxacin resistance in a background of clarithromycin- and metronidazole-resistant Helicobacter pylori in Vietnam. Int J Antimicrob Agents. 2015;45:244–248. doi: 10.1016/j.ijantimicag.2014.10.019. [DOI] [PubMed] [Google Scholar]
- 6.Sun QJ, Liang X, Zheng Q, Gu WQ, Liu WZ, Xiao SD, Lu H. Resistance of Helicobacter pylori to antibiotics from 2000 to 2009 in Shanghai. World J Gastroenterol. 2010;16:5118–5121. doi: 10.3748/wjg.v16.i40.5118. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 7.Su P, Li Y, Li H, Zhang J, Lin L, Wang Q, Guo F, Ji Z, Mao J, Tang W, et al. Antibiotic resistance of Helicobacter pylori isolated in the Southeast Coastal Region of China. Helicobacter. 2013;18:274–279. doi: 10.1111/hel.12046. [DOI] [PubMed] [Google Scholar]
- 8.Ji Z, Han F, Meng F, Tu M, Yang N, Zhang J. The Association of Age and Antibiotic Resistance of Helicobacter Pylori: A Study in Jiaxing City, Zhejiang Province, China. Medicine (Baltimore) 2016;95:e2831. doi: 10.1097/MD.0000000000002831. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 9.Gehlot V, Mahant S, Mukhopadhyay AK, Das K, De R, Kar P, Das R. Antimicrobial susceptibility profiles of Helicobacter pylori isolated from patients in North India. J Glob Antimicrob Resist. 2016;5:51–56. doi: 10.1016/j.jgar.2015.09.009. [DOI] [PubMed] [Google Scholar]
- 10.Pandya HB, Agravat HH, Patel JS, Sodagar NR. Emerging antimicrobial resistance pattern of Helicobacter pylori in central Gujarat. Indian J Med Microbiol. 2014;32:408–413. doi: 10.4103/0255-0857.142256. [DOI] [PubMed] [Google Scholar]
- 11.Maleknejad S, Mojtahedi A, Safaei-Asl A, Taghavi Z, Kazemnejad E. Primary Antibiotic Resistance to Helicobacter pylori Strains Isolated From Children in Northern Iran: A Single Center Study. Iran J Pediatr. 2015;25:e2661. doi: 10.5812/ijp.2661. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 12.Kohanteb J, Bazargani A, Saberi-Firoozi M, Mobasser A. Antimicrobial susceptibility testing of Helicobacter pylori to selected agents by agar dilution method in Shiraz-Iran. Indian J Med Microbiol. 2007;25:374–377. doi: 10.4103/0255-0857.37342. [DOI] [PubMed] [Google Scholar]
- 13.Abadi AT, Taghvaei T, Mobarez AM, Carpenter BM, Merrell DS. Frequency of antibiotic resistance in Helicobacter pylori strains isolated from the northern population of Iran. J Microbiol. 2011;49:987–993. doi: 10.1007/s12275-011-1170-6. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 14.Siavoshi F, Safari F, Doratotaj D, Khatami GR, Fallahi GH, Mirnaseri MM. Antimicrobial resistance of Helicobacter pylori isolates from Iranian adults and children. Arch Iran Med. 2006;9:308–314. [PubMed] [Google Scholar]
- 15.Fallahi GH, Maleknejad S. Helicobacter pylori culture and antimicrobial resistance in Iran. Indian J Pediatr. 2007;74:127–130. doi: 10.1007/s12098-007-0003-4. [DOI] [PubMed] [Google Scholar]
- 16.Siavoshi F, Saniee P, Latifi-Navid S, Massarrat S, Sheykholeslami A. Increase in resistance rates of H. pylori isolates to metronidazole and tetracycline--comparison of three 3-year studies. Arch Iran Med. 2010;13:177–187. [PubMed] [Google Scholar]
- 17.Sirous M, Mehrabadi JF, Daryani N, Eshraghi S, Hajikhani S, Shirazi M. Prevalence of antimicrobial resistance in Helicobacter pylori isolates from Iran. Afr J Biotechnol. 2010;9:5962–5965. [Google Scholar]
- 18.Rafeey M, Ghotaslou R, Nikvash S, Hafez AA. Primary resistance in Helicobacter pylori isolated in children from Iran. J Infect Chemother. 2007;13:291–295. doi: 10.1007/s10156-007-0543-6. [DOI] [PubMed] [Google Scholar]
- 19.Kim JJ, Kim JG, Kwon DH. Mixed-infection of antibiotic susceptible and resistant Helicobacter pylori isolates in a single patient and underestimation of antimicrobial susceptibility testing. Helicobacter. 2003;8:202–206. doi: 10.1046/j.1523-5378.2003.00145.x. [DOI] [PubMed] [Google Scholar]
- 20.Goh KL, Navaratnam P. High Helicobacter pylori resistance to metronidazole but zero or low resistance to clarithromycin, levofloxacin, and other antibiotics in Malaysia. Helicobacter. 2011;16:241–245. doi: 10.1111/j.1523-5378.2011.00841.x. [DOI] [PubMed] [Google Scholar]
- 21.Siddiqui TR, Ahmed W, Arif A, Bibi S, Khan A. Emerging trends of antimicrobial resistance in Helicobacter pylori isolates obtained from Pakistani patients: The need for consideration of amoxicillin and clarithromycin. J Pak Med Assoc. 2016;66:710–716. [PubMed] [Google Scholar]
- 22.Mendonça S, Ecclissato C, Sartori MS, Godoy AP, Guerzoni RA, Degger M, Pedrazzoli J Jr. Prevalence of Helicobacter pylori resistance to metronidazole, clarithromycin, amoxicillin, tetracycline, and furazolidone in Brazil. Helicobacter. 2000;5:79–83. doi: 10.1046/j.1523-5378.2000.00011.x. [DOI] [PubMed] [Google Scholar]
- 23.Godoy AP, Ribeiro ML, Benvengo YH, Vitiello L, Miranda Mde C, Mendonça S, Pedrazzoli J Jr. Analysis of antimicrobial susceptibility and virulence factors in Helicobacter pylori clinical isolates. BMC Gastroenterol. 2003;3:20. doi: 10.1186/1471-230X-3-20. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 24.Eisig JN, Silva FM, Barbuti RC, Navarro-Rodriguez T, Moraes-Filho JP, Pedrazzoli Jr J. Helicobacter pylori antibiotic resistance in Brazil: clarithromycin is still a good option. Arq Gastroenterol. 2011;48:261–264. doi: 10.1590/s0004-28032011000400008. [DOI] [PubMed] [Google Scholar]
- 25.Ogata SK, Gales AC, Kawakami E. Antimicrobial susceptibility testing for Helicobacter pylori isolates from Brazilian children and adolescents: comparing agar dilution, E-test, and disk diffusion. Braz J Microbiol. 2015;45:1439–1448. doi: 10.1590/s1517-83822014000400039. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 26.Ogata SK, Godoy AP, da Silva Patricio FR, Kawakami E. High Helicobacter pylori resistance to metronidazole and clarithromycin in Brazilian children and adolescents. J Pediatr Gastroenterol Nutr. 2013;56:645–648. doi: 10.1097/MPG.0b013e31828b3669. [DOI] [PubMed] [Google Scholar]